$3.44
5.85% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Fulcrum Therapeutics Inc Stock price

$3.44
+0.25 7.84% 1M
-3.77 52.29% 6M
-3.31 49.04% YTD
-1.40 28.93% 1Y
-11.77 77.38% 3Y
-11.57 77.08% 5Y
-10.06 74.52% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.19 5.85%
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Key metrics

Market capitalization $185.55m
Enterprise Value $-62.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 7.15
EV/Sales (TTM) EV/Sales -0.77
P/S ratio (TTM) P/S ratio 2.29
P/B ratio (TTM) P/B ratio 0.72
Revenue growth (TTM) Revenue growth 2,987.86%
Revenue (TTM) Revenue $80.87m
EBIT (operating result TTM) EBIT $-28.40m
Free Cash Flow (TTM) Free Cash Flow $-8.74m
Cash position $257.23m
EPS (TTM) EPS $-0.31
P/E forward negative
P/S forward 2.31
EV/Sales forward negative
Short interest 9.92%
Show more

Is Fulcrum Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Fulcrum Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Fulcrum Therapeutics Inc forecast:

2x Buy
25%
5x Hold
63%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Fulcrum Therapeutics Inc forecast:

Buy
25%
Hold
63%
Sell
13%

Financial data from Fulcrum Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
81 81
2,987% 2,987%
100%
- Direct Costs 1.79 1.79
21% 21%
2%
79 79
21,867% 21,867%
98%
- Selling and Administrative Expenses 36 36
9% 9%
45%
- Research and Development Expense 69 69
0% 0%
86%
-27 -27
75% 75%
-33%
- Depreciation and Amortization 1.79 1.79
21% 21%
2%
EBIT (Operating Income) EBIT -28 -28
74% 74%
-35%
Net Profit -18 -18
82% 82%
-22%

In millions USD.

Don't miss a Thing! We will send you all news about Fulcrum Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulcrum Therapeutics Inc Stock News

Neutral
Seeking Alpha
12 days ago
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Financial Officer Iain Fraser - Senior Vice President, Early Development Patrick Horn - Chief Medical Officer Conference Call Participants Matthew Biegler - Oppenheimer Dae Gon Ha - Stifel Edward Tentho...
Neutral
GlobeNewsWire
14 days ago
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel Healthcare Conference in New York City on November...
Neutral
GlobeNewsWire
20 days ago
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on Wednesday, November 13, 2024, before the U.S. fin...
More Fulcrum Therapeutics Inc News

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Sapir
Employees 76
Founded 2015
Website www.fulcrumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today